Four Years of WCMSA Data: 6 Numbers That Could Change Your MSA Strategy 

October 29, 2026

Four-year comparison of Tower MSA Partners’ CMS-approved WCMSA outcomes and CMS national averages from 2022 through 2025

One number can get your attention. Six numbers can change how you look at MSA strategy. 

For years, Tower MSA Partners has been tracking outcomes across Medicare Set-Aside preparation, clinical intervention, CMS review, pharmacy exposure, conditional payment resolution, and claim closure. 

The results raise some important questions. 

  • What if the first MSA isn’t necessarily the final MSA? 
  • What does it take to reduce an allocation while maintaining a defensible approach to CMS? 
  • How much can accurate pharmacy and clinical information change projected Medicare exposure? 
  • And what happens to settlement costs when Medicare’s interests are addressed early rather than at the end of the claim? 

Those are the questions behind Tower’s new Workers’ Compensation MSP Outcomes & Regulatory Insights Report and the blog series that follows. 

Tower MSA Partners’ four-year WCMSA data shows that early clinical intervention and strong Medicare Secondary Payer compliance can lower settlement costs without sacrificing CMS defensibility. From 2022 through 2025, Tower’s average CMS-approved WCMSA remained below the national average every year. 

In 2025, Tower’s average CMS-approved Workers’ Compensation Medicare Set-Aside was $18,477 lower than the CMS national average. Across 100 annual MSA submissions, that difference represents approximately $1.85 million in projected settlement exposure. 

 But the purpose of the Outcomes Report isn’t simply to highlight a difference between Tower’s results and a national benchmark. 

The more important question is why the results look the way they do. 

This blog series will move beyond the topline results to examine the decisions behind them and what claims leaders can apply to their own programs. 

What Four Years of WCMSA Data Show 

Tower’s average CMS-approved WCMSA remained below the CMS national average in each year reviewed: 

Year CMS Average WCMSA Tower Average Approved WCMSA
2022 $81,572 $59,051
2023 $86,453 $78,423
2024 $85,927 $69,867
2025 $86,169 $67,692

Source: Tower MSA Partners, Workers’ Compensation MSP Outcomes & Regulatory Insights Report, Section 2.3. Differences were calculated from the reported annual averages. 

The Six Numbers at a Glance 

  1. $18,477 lower: In 2025, Tower’s average CMS-approved WCMSA was $18,477 below the CMS national average. What does that difference tell us about MSA strategy—and what should claims professionals be asking before accepting an initial allocation? 
  1. 33% to 64% in clinical reductions: Tower’s average annual clinical reductions fell within this range. What can current clinical information reveal that may not be apparent from the records used to prepare an initial MSA? 
  1. 76% to 88% CMS alignment: Tower’s data showed substantial alignment between its reduced allocations and CMS outcomes. What does that tell us about the relationship between MSA savings and CMS defensibility? 
  1. 86% with $0 opioid allocation: In 2025, 86% of Tower’s CMS-approved WCMSAs contained no projected opioid cost., How do medication histories, physician engagement, and pharmacy oversight affect future Medicare exposure? 
  1. 82% of conditional payment demands reduced to $0: A Medicare conditional payment demand isn’t necessarily the final number that must be paid. What does Tower’s data tell us about the importance of investigating and resolving Medicare’s interests before settlement? 
  1. $9 million to $12 million in annual savings: Tower’s data shows the scale of savings associated with Physician follow-up and pharmacy optimization. What happens when these opportunities are considered across an entire claims portfolio rather than one claim at a time? 

The results are directional benchmarks, not promises for an individual claim or portfolio. Their value is showing where process and evidence can change an outcome. 

Why These WCMSA Findings Belong Together 

The first MSA can change settlement authority. Clinical intervention can change the allocation. CMS alignment indicates whether the approach remains defensible. Pharmacy decisions affect the long-term cost of a claim. Conditional payments and $0 MSA documentation influence risk at and after settlement. 

Looking at any one metric alone misses the larger point. The final financial outcome is shaped by how well these steps work together. 

That is the purpose of this series. Each article will take one decision point from the Outcomes Report and translate it into a practical question for claims, legal, compliance, and risk leaders. 

What the Outcomes Report Blog Series Will Cover 

1. Accepting the First MSA Is Often the Costliest Decision: What Four Years of CMS Data Reveals 

When should an initial MSA be accepted, and when do outdated medications, unsupported treatment, or incomplete records justify a second look? 

2. What the CMS Alignment Index Actually Tells You About Your MSA Strategy 

How can a program challenge preventable over-allocation without sacrificing predictable, defensible CMS outcomes? 

3. Opioid Exposure in MSAs: How 86% of Tower Cases Reached $0 and What It Takes to Get There 

What clinical documentation, physician engagement, and pharmacy oversight are required to ensure an MSA reflects the treatment actually expected? 

4. CMS No Longer Reviews $0 MSAs: What That Means for Your Post-Settlement Exposure 

CMS stopped accepting or reviewing $0 WCMSA proposals effective July 17, 2025. What does that change mean for documentation, governance, and post-settlement exposure? CMS outlines the policy on its official WCMSA What’s New page. 

5. 82% of Conditional Payment Demands Reduced to $0: The Post-Settlement Number Most Programs Ignore 

What should claims teams verify before treating a conditional payment demand as an amount that must be paid? 

6. MSP as Enterprise Risk: What 2022 to 2025 Performance Data Should Change About How You Budget for Settlements 

How should MSA, CMS, pharmacy, conditional payment, and reporting outcomes inform reserves, settlement authority, loss development, and capital planning? 

What Should Claims Leaders Do Now? 

Start by comparing Tower’s findings with your own program: 

  • Compare average and median approved WCMSAs with relevant CMS benchmarks. 
  • Measure how often clinical intervention changes an allocation and how much it saves. 
  • Track prescription drug and opioid exposure in approved WCMSAs. 
  • Review proposed-to-approved variance, development letters, and conditional payment outcomes. 
  • Determine whether Section 111 reporting and conditional payment work begin early enough to support settlement. 

Tower’s Medicare Set-Aside services and Medicare lien resolution connect these decisions through claim closure. 

Review the full Workers’ Compensation MSP Outcomes & Regulatory Insights Report and return to this page as each article is published. 

To compare your program with these benchmarks, submit a referral to Tower MSA Partners. 

About the Outcomes Report Data 

The report uses Tower MSA Partners’ aggregated, anonymized outcomes from WCMSAs and related MSP services between 2022 and 2025. CMS and market comparisons draw on published WCMSA statistics and related public information. The figures are intended to provide directional benchmarks and identify questions worth asking. They do not guarantee a particular reduction, approval, or settlement result for an individual claim or portfolio. 

Frequently Asked Questions About Four Years of WCMSA Data

What Is a WCMSA? 

A WCMSA allocates part of a workers’ compensation settlement for future Medicare-covered medical services related to the workers’ compensation injury, illness, or disease. 

What Is the Tower Outcomes Report Blog Series? 

This article introduces six follow-up posts examining what Tower’s 2022 through 2025 WCMSA and MSP outcomes mean for MSA cost, CMS alignment, pharmacy exposure, conditional payments, settlement strategy, and post-settlement risk. 

Does CMS Still Review $0 WCMSAs? 

No. Effective July 17, 2025, CMS stopped accepting or reviewing WCMSA proposals with a $0 allocation. However, CMS still allows $0 MSAs if they fit certain criteria. Parties should consult with Tower to determine whether their settlement fits into these guidelines. 

What are Medicare conditional payments? 

 A temporary payment made by Medicare for a beneficiary’s medical services when another primary insurance plan (such as liability insurance, no-fault auto insurance, or workers’ compensation) is responsible for paying but has not paid or will not pay promptly. 

Home » Medicare Set-Asides

Top 10 Lessons from the Tower MSA Case Study Series 

October 1, 2026

Tower MSA Partners Top 10 Lessons from the MSA Case Study Series

Tower MSA Partners’ case study series reveals ten important lessons for claims professionals. Drawing from real-world cases, the series demonstrates how early intervention, clinical oversight, accurate documentation, and consistent review can improve Medicare Set-Aside and settlement outcomes. 

The cases have involved high-cost medications, outdated treatment plans, inaccurate allocations, conditional payment demands, amended reviews, and stalled legacy claims. 

Although every claim was different, one theme appeared repeatedly: meaningful MSA savings begin with accuracy. 

Here are the ten most important lessons from the series and what they mean for claims professionals. 

Lesson 1: Intervene Before MSA Preparation 

Early review can prevent unsupported treatment and pharmacy expenses from entering an allocation in the first place. 

In How Pre-MSA Triage Prevented $774K in Unnecessary Costs, Tower MSA Partners identified medical and pharmaceutical issues before the MSA was prepared. This early intervention prevented $774,583 in projected costs. 

What this means for claims teams:  

Do not wait until an MSA is ready for submission to question outdated treatment plans, medication histories, or unsupported projections. 

Lesson 2: Physician Peer Review Can Transform a High-Cost MSA 

Some medical questions require more than an administrative review. They require a qualified physician who can determine whether treatment remains clinically appropriate. 

In $1 Million Saved with Physician Peer Review, Tower identified overlapping therapies, high-cost medications, and treatment that had not been reevaluated for clinical necessity. Physician involvement, treatment changes, and supporting documentation ultimately produced more than $1 million in MSA savings. 

What this means for claims teams:  

Physician peer review can provide the clinical evidence needed to address complex, outdated, or duplicative treatment. 

Lesson 3: A Second Opinion Can Prevent an Expensive Mistake 

An MSA can look complete and still contain inaccurate information. 

In A $98K Mistake Avoided with a Second Opinion MSA Review, Tower found duplicate treatment, outdated information, and a discontinued high-cost medication in an allocation prepared by another vendor. Correcting these issues prevented approximately $98,000 in unnecessary funding. 

What this means for claims teams:  

Consider a second opinion MSA review when an allocation appears unusually high, includes substantial pharmacy exposure, or does not match the most recent medical records. 

Lesson 4: MSA Optimization Starts with Accuracy 

MSA optimization is not about cutting medically necessary care. It is about making sure every projected treatment, medication, frequency, and cost is supported by current evidence. 

In Trimming the Fat: $175K in Savings Through MSA Optimization, Tower identified duplicate entries, outdated treatment, replaced medications, and unsupported therapy projections. Correcting those discrepancies reduced the allocation by $175,000. 

What this means for claims teams:  

Sustainable MSA savings come from correcting inaccurate projections, not from targeting an arbitrary reduction. 

Lesson 5: Physician Follow-Up Can Fill Critical Information Gaps 

Medical records do not always clearly state whether a medication remains active, therapy is still recommended, or a treatment plan has changed. 

In $231K in Savings from Free Physician Follow-Up, Tower contacted the treating provider to confirm the claimant’s current treatment and medication needs. The resulting documentation supported a $231,487 reduction, and CMS accepted the revised allocation without development. 

What this means for claims teams:  

When the records do not answer an important clinical question, physician follow-up may provide the missing evidence. 

Lesson 6: Clinical Oversight Must Continue as Claims Change 

An MSA reflects the information available at one point in time, but claims continue to evolve. 

Medications are discontinued. Dosages change. Therapy frequency decreases. Providers revise their recommendations. Without continued review, an allocation can stop reflecting the claimant’s actual care. 

In $210K Saved: Why Clinical Oversight Is the Hidden MSA Advantage, Tower identified medications that were no longer prescribed, unsupported treatment, and frequencies that did not match current care. The review reduced the projected allocation by $210,143. 

What this means for claims teams:  

Clinical review should not be treated as a one-time event, especially when a claim has a long treatment history or multiple prescribing providers. 

Lesson 7: Updated Evidence Can Move Legacy Claims Forward 

 Legacy claims often remain open because the available information no longer provides an accurate picture of the claimant’s care. 

In From Backlog to Breakthrough: Reducing 43 Percent of Legacy Claims, Tower reviewed outdated treatment histories, discontinued medications, and old medical projections. By replacing outdated assumptions with current evidence, Tower helped move 43% of the payer’s legacy claim backlog toward resolution. 

What this means for claims teams: 

A claim that has been open for years is not necessarily impossible to settle. It may simply need an updated legacy claims settlement strategy. 

Lesson 8: Verify Every Conditional Payment Charge 

A Medicare conditional payment demand may include unrelated treatment, incorrect dates, duplicate charges, or services associated with broad diagnosis codes. 

In How Tower Reduced Conditional Payments to $0, Tower reviewed each charge against the claimant’s medical history and documented why unrelated services should be removed. Medicare accepted the dispute and reduced the conditional payment demand to zero. 

What this means for claims teams:  

Do not assume every charge listed in a conditional payment demand is the payer’s responsibility. Each line item should be reviewed and validated. 

Lesson 9: New Medical Evidence Can Support an Amended Review 

A CMS-approved MSA may no longer reflect the claimant’s medical needs if treatment changes after approval. 

In Amended Review Strategy Drops MSA by $101K, updated records showed that medications had been discontinued, therapy frequency had decreased, and previously projected testing was no longer recommended. Tower used this new evidence to support an amended review that reduced the MSA by $101,312. 

CMS allows for a one-time Amended Review MSA submission in situations like these, where medical costs have decreased since the original MSA was approved. 

What this means for claims teams:  

An existing approval should not end the review process when significant, documented treatment changes occur. 

Lesson 10: The Strongest Outcomes Come from a Coordinated Strategy 

The case study series shows that no single review method produces every result. The strongest outcomes came from combining early intervention, clinical oversight, current medical evidence, physician engagement, accurate documentation, and clear communication among everyone involved in the claim. 

Tower MSA Partners does more than identify potential errors or outdated treatment. Its clinical and compliance teams help translate those findings into documented, defensible actions that support cost containment and move claims toward settlement. 

What this means for claims teams:  

Better outcomes rarely come from one isolated step. They come from coordinating the clinical, compliance, claims, and settlement strategy from beginning to end. 

What These MSA Lessons Have in Common 

These cases involved different claims, medical histories, and settlement challenges. Yet the strongest outcomes shared several qualities: 

  • Claims were reviewed before outdated assumptions became permanent obstacles. 
  • Medical records were compared with projected future care. 
  • Clinical professionals evaluated treatment and pharmacy exposure. 
  • Treating providers were contacted when the records left important questions unanswered. 
  • Recommended changes were supported by documentation. 
  • Claims, clinical, legal, and compliance teams remained aligned. 
  • Savings resulted from accuracy, not from removing medically necessary care. 

This is the larger lesson from the series: MSA cost containment and Medicare compliance should not be treated as competing priorities. When an allocation accurately reflects current medical evidence, it can support both. 

Experience Behind the Results 

Tower MSA Partners provides Medicare Secondary Payer compliance and Medicare Set-Aside services to insurers, self-insured employers, third-party administrators, and attorneys. 

Tower’s clinical and compliance professionals combine medical review, regulatory knowledge, claims experience, and technology-enabled processes to help clients: 

  • Prepare accurate and defensible MSAs. 
  • Identify appropriate opportunities for MSA savings. 
  • Address complex treatment and pharmacy exposure. 
  • Resolve conditional payment demands and Medicare liens. 
  • Improve Section 111 reporting coordination. 
  • Move difficult and legacy claims toward settlement. 

The outcomes featured in this series reflect actual Tower MSA Partners case studies. Results vary based on each claim’s facts, medical evidence, documentation, and applicable CMS guidance. 

Explore the complete Tower MSA Partners case study library for more examples of these strategies in action. 

Put These MSA Lessons to Work 

If an inaccurate allocation, outdated treatment plan, conditional payment demand, or legacy claim is delaying settlement, the next step is to determine what the current evidence supports. 

Submit a referral or contact Tower MSA Partners to discuss the claim and identify the appropriate review strategy. 

Frequently Asked Questions About Medicare Set-Asides and Cost Savings 

What Is the Biggest Lesson from Tower MSA Partners’ Case Study Series? 

The biggest lesson is that MSA accuracy depends on current medical evidence. Early intervention, clinical oversight, physician input, and documentation validation can identify unsupported projections and produce a more accurate allocation. 

How Does Clinical Oversight Affect MSA Outcomes? 

Clinical oversight compares projected treatment and medications with the claimant’s documented medical needs. It can identify outdated, duplicative, discontinued, or unsupported care that may be inflating the allocation. 

When Should a Payer Request a Second Opinion MSA Review? 

A second opinion may be appropriate when an allocation appears unusually high, contains significant pharmacy exposure, conflicts with recent medical records, or was prepared before major treatment changes occurred. 

Can an Approved Medicare Set-Aside Be Changed? 

An approved WCMSA may qualify for an amended review when the claim meets current CMS requirements and significant changes are supported by updated medical or financial documentation. 

Why Is Documentation Important in an MSA Review? 

Documentation connects clinical findings to the final allocation. Clear, current medical evidence helps explain treatment changes, support accurate projections, and create a more defensible MSA. 

How Does Tower MSA Partners Help Reduce MSA Costs? 

Tower MSA Partners uses early claim review, clinical oversight, pharmacy analysis, physician engagement, documentation validation, and regulatory expertise to identify unsupported projections and prepare accurate, defensible MSAs. 

Who Does Tower MSA Partners Work With? 

Tower MSA Partners works with insurers, self-insured employers, third-party administrators, and attorneys to manage Medicare Secondary Payer compliance, reduce claim costs, and move complex claims toward settlement. 

Why Isn’t the Claim Settling? The MSP Issues Beyond the MSA that Can Derail a Settlement

September 2, 2026

By Louis Porrazzo, Esq., Chief Legal Officer, Tower MSA Partners and Claimify

For the past 25 years, the Medicare Set-Aside Arrangement (MSA) has been treated as the crown jewel of Medicare Secondary Payer (MSP) compliance. And rightfully so! An inappropriately high-dollar MSA can derail a settlement, an improperly prepared MSA may not survive review by the Centers for Medicare and Medicaid Services (CMS), and an insufficiently funded MSA can leave the injured worker in a Medicare quagmire.

During that same timeframe, the industry has become reasonably proficient at ensuring that an MSA is appropriately calculated, that an MSA submitted to Medicare has a strong likelihood of approval near the submitted amount, and that the MSA is properly funded and administered.

And yet, parties still routinely encounter MSP-related issues that prevent or delay settlement.  Even when an MSA has been prepared, submitted, approved or indemnified, and funding and administration have been arranged, the parties still carry ongoing MSP obligations that must be met.

Improper Section111 reporting, failure to properly address conditional payments, and inconsistent claim information can derail a settlement at the eleventh hour. Individually, each of these issues can be managed without much difficulty. The challenge is that they are rarely identified early enough to be handled as routine compliance work.

MSP compliance must be fully integrated into all aspects of claims handling. If the first meaningful discussion about Medicare occurs during settlement negotiations, the parties are already at a disadvantage.

Here are five MSP-related issues to address before the settlement becomes derailed:

1. Section111 Data is Inconsistent

The handling adjuster is responsible for maintaining accurate claim information, ensuring appropriate ICD codes are used, and paying only for treatment and services for which the payer is responsible. Defense counsel may be litigating the accepted body parts, correct date of injury, causal relationship, and other aspects of the claim. And some organizations have entire departments or outside vendors dedicated to Medicare reporting. Their efforts should be aligned. Too often, they are not.

Dates of injury, ICD codes, ORM (Ongoing Responsibility for Medicals) status and termination dates, TPOC (Total Payment Obligation to the Claimant) information, and other reporting data should accurately reflect the claim being settled. This has become even more important as CMS has expanded Section111 reporting requirements to include WCMSA information and increased its focus on reporting timeliness and accuracy. CMS began quarterly Section 111 reporting audits in the first quarter of 2026, sampling accepted records and assessing civil money penalties where ORM assumption or TPOC was reported outside the required timeframe. Reporting data that was merely untidy a year ago now carries a direct financial consequence.

Inconsistent data can create significant problems. Multiple Medicare records may be established or associated with a claim, potentially triggering unnecessary recovery activity. Inaccurate information can complicate settlement documentation and reporting. And improper coding may cause confusion regarding which injuries and medical treatment are actually related to the workers’ compensation claim.

Before the parties settle, they should ensure that what is reported under Section111 matches the claim that is about to close.

2. Ambiguity Surrounding ORM

When an accepted workers’ compensation claim is settled and the payer’s responsibility for medical treatment ends, ORM generally needs to be terminated, and applicable TPOC information reported under Section 111. The key question is whether ORM should have been accepted in the first place.

  • When did responsibility for medical treatment begin?
  • Was it ever accepted or denied?
  • Does it remain open?
  • Is there a legitimate basis for terminating ORM?
  • If so, when should the termination be reported?

These decisions should not be made automatically simply because a claim is established at the front end or the claim is settling on the back end. Inaccurately accepting ORM can create problems beyond Section111 reporting itself, including unnecessary conditional payment recovery efforts and confusion regarding accepted injuries.

Settlement is a good time to review Section111 and ORM activities, but it should not be the first time these questions are asked.

3. Forgotten Conditional Payments

Far too often, conditional payments are an afterthought.  The industry has become very good at knowing how to prepare an MSA, how to obtain approval when submission is appropriate, how to fund it, and how to administer it.  But conditional payments still go unaddressed until the last minute. 

CMS may seek reimbursement for payments it believes are related to the workers’ compensation claim, including charges that the payer believes are unrelated or otherwise not their responsibility. Failing to investigate and address those payments early can lead to unnecessary reimbursement demands and delays in bringing the claim to final resolution.

Organizations can save money by addressing conditional payments in a timely fashion. Just as importantly, accurate Section 111 reporting and proper conditional payment resolution can reduce confusion over responsibility for medical treatment. These issues can usually be resolved, but resolution takes time.  A conditional payment issue discovered months before settlement is a compliance task. The same issue discovered days before settlement can become a settlement problem.

4. When Everyone Owns MSP Compliance, No One Does

It is important for all parties to align on MSP-related activities and expectations.  The adjuster and defense attorney should be in lockstep when it comes to handling the MSA, conditional payments or Section 111 questions.  Both parties should have a working relationship with the MSP vendor of choice.  And the claimant’s counsel should understand their obligations in denied workers’ compensation cases.

MSP compliance involves multiple interconnected obligations, and treating each one as an independent transaction creates opportunities for things to be missed. Each party should know which tasks belong to them. Before settlement discussions begin, parties should understand:

  • What is accepted and what remains denied or disputed?
  • Is the claimant Medicare eligible or reasonably expected to become Medicare eligible?
  • Is §111 reporting accurate, including ORM status?
  • Who is responsible for resolving conditional payments?
  • What is the strategy for MSA preparation, funding, and administration?
  • If an MSA is appropriate, will the parties pursue CMS submission or utilize another risk-management approach such as indemnification?

While different people will be handling different aspects of MSP compliance, it is important to have one person or department leading the charge and bringing all parties together to ensure MSP compliance.

5. MSP Protocol vs. “Getting an MSA”

Every entity should have a defined MSP protocol in place to ensure compliance. The mindset should shift from “getting an MSA” to “complete MSP compliance.” Any settlement strategy should include Medicare from the beginning.

Is there a discrepancy in treatment? Address it during claims handling so it doesn’t become an issue at settlement.

Is the case denied? Do not automatically assume that ORM should be reported. Analyze whether responsibility for medical treatment has actually been accepted and report accordingly.

Is the claimant treating body parts unrelated to the injury? Do not pay for that treatment. Those payments can inflate the MSA and complicate CMS approval.

By the time everyone has agreed on a settlement number, expectations have been created and momentum matters. An unexpected Medicare issue at that stage does more than increase costs. It can destroy that momentum and prevent the settlement from closing.

Final Thoughts

MSP compliance should be built into the overall claims strategy from the beginning. Section 111 reporting, conditional payments, future medical exposure, and settlement all intersect, and problems in one area can quickly affect another. A well-defined MSP protocol gives the parties an opportunity to identify and resolve those issues while there is still time to keep the claim moving toward settlement.

The best time to discover a Medicare problem is when there is still time to do something about it. When the claimant wants to settle, counsel agrees to settlement terms, the adjuster has authority, and the MSA is complete, the last thing anyone wants to hear is “We still have a Medicare issue.” A well-built MSP Protocol is what keeps that sentence out of the room.

On Wednesday, September 16, at 2:00 p.m. ET, join Tower’s Chief Legal Officer, Lou Porrazzo, and Tower’s Chief Compliance Officer, Dan Anders, for a practical discussion of five MSP-related issues that commonly delay workers’ compensation settlements and what claims professionals can do to identify and resolve them earlier.

Register for the webinar today!

Frequently Asked Questions About MSP Issues That Delay Settlement

Why do workers’ compensation settlements get delayed by Medicare issues?

Most delays come from issues outside the Medicare Set-Aside itself. Inconsistent Section 111 data, unresolved conditional payments, and unclear ORM status surface late in negotiations, when the parties have already agreed on a number and have no time to fix them.

What Section 111 data should be verified before settlement?

Confirm that the date of injury, ICD codes, ORM status and termination date, and TPOC information all match the claim being settled. Since April 2025, WCMSA amounts must also be reported. Mismatched data can trigger duplicate Medicare records and unnecessary recovery activity.

When should ORM be terminated on a workers’ compensation claim?

ORM generally terminates when the payer’s responsibility for medical treatment ends, which usually coincides with settlement. The more important question is whether ORM should have been accepted in the first place, because accepting it in error creates conditional payment exposure that did not need to exist.

Who is responsible for resolving conditional payments in a settlement?

Responsibility should be assigned explicitly before settlement discussions begin, typically to the adjuster, defense counsel, or the MSP vendor. When no one owns it, conditional payments surface days before closing, at which point they become a settlement problem rather than a compliance task.

Does an approved MSA mean the claim is MSP compliant?

No. An approved and funded MSA addresses future medical exposure only. Section 111 reporting accuracy, ORM status, and conditional payment resolution are separate obligations that continue independently and can hold up a settlement on their own.

Louis Porrazzo, Esq. serves as Chief Legal Officer for Tower MSA Partners. A recognized authority on Medicare Secondary Payer (MSP) compliance, Lou is a frequent national speaker and author known for translating complex Medicare compliance issues into practical strategies for claims professionals, attorneys, insurers, and self-insured organizations. He is licensed to practice law in the Commonwealth of Massachusetts and brings extensive experience in MSP compliance, workers’ compensation, and general liability defense. Outside of his professional work, Lou chairs the Kids’ Chance of Massachusetts Fundraising Committee and is a CrossFit Level 2 Certified Trainer. He can be reached at Louis.Porrazzo@TowerMSA.com.

Amended Review Strategy Drops MSA by $101K

July 20, 2026

Tower MSA Partners amended review case study showing $101,312 in Medicare Set Aside savings

In Tower MSA Partners’ last post, How Tower Reduced Conditional Payments to $0, we explained how Tower reduced Medicare conditional payments to zero through detailed review and accurate documentation. This month, we focus on a case where an amended review dramatically changed the outcome of an already CMS-approved MSA. A payer requested help after receiving an unexpectedly high counter-higher from CMS. Through an amended review supported by updated medical records and clinical oversight, Tower corrected outdated projections and reduced the MSA by $101,312. This case shows how persistence and accuracy create better settlement outcomes.

Identifying the Problem

After an MSA had been submitted and approved by CMS, new medical records revealed important changes in the claimant’s treatment plan. Several medications had been discontinued, therapy frequency had decreased, and previously projected diagnostic testing was no longer recommended. As a result, the approved allocation no longer reflected the claimant’s current treatment needs and overstated projected future medical costs.

The allocation no longer aligned with the claimant’s current medical condition or ongoing treatment plan. Moving forward with settlement based on outdated projections would have resulted in funding medical expenses that were no longer supported by the available clinical evidence. The payer needed an amended review to ensure the MSA accurately reflected current medical.

Turning New Medical Evidence Into $101K in Savings

Tower MSA Partners conducted a comprehensive amended review to evaluate the newly available medical information and determine its impact on future medical cost projections.

The clinical team analyzed updated medical records, treatment histories, prescription information, and provider recommendations. During the review, several medications included in the original allocation were confirmed as discontinued and no longer medically necessary. Therapy projections were adjusted to reflect the claimant’s current treatment frequency, and future diagnostic testing recommendations were updated based on the most recent provider documentation.

Using this information, Tower prepared an Amended Review Medicare Set Aside allocation supported by detailed clinical rationale and updated medical evidence. The amended submission clearly demonstrated why the original projections no longer reflected the claimant’s current treatment needs and how the revised allocation more accurately represented future medical exposure.

CMS reviewed the amended Medicare Set Aside submission and accepted the updated allocation, resulting in a reduction of $101,312.

Outcome

  • MSA Reduction: $101,312
  • Strategy: Amended Review
  • Key Findings: Discontinued medications, reduced therapy frequency, and updated diagnostic recommendations
  • CMS Result: Revised allocation accepted
  • Impact: More accurate funding and lower settlement costs

Collaboration and Communication

Successful amended reviews require more than updated medical records. They also depend on clear communication among stakeholders involved in the settlement process.

Tower MSA Partners worked closely with the claims professional to review the updated treatment information and ensure the rationale behind each amendment was thoroughly documented. When necessary, providers and defense counsel were consulted to verify treatment changes and eliminate potential discrepancies before resubmission.

This collaborative approach helped streamline the review process and provided CMS with a well-supported allocation backed by current medical evidence. Because the documentation was complete and clearly explained, CMS accepted the revised allocation without requesting additional information.

Why Amended Reviews Matter

Workers’ compensation claims are dynamic. Treatment plans change, medications are discontinued, and providers adjust recommendations based on a claimant’s progress. When those changes occur after an MSA has been prepared or submitted, failing to update the allocation can result in unnecessary funding and inflated settlement costs.

Amended reviews help ensure that Medicare Set Aside allocations remain accurate, defensible, and aligned with current medical evidence. By incorporating updated treatment information before settlement, payers can avoid overfunding future medical expenses while maintaining compliance with CMS requirements.

The amended review identified treatment projections that no longer reflected the claimant’s current medical status. Without the review, the payer would have funded more than $101,000 in projected medical costs that were no longer supported by the treatment record.

Key Takeaways

  • Amended reviews help ensure Medicare Set Aside allocations reflect current medical necessity.
  • Updated medical records can reveal opportunities to reduce future medical cost projections.
  • Discontinued medications and changes in treatment frequency can have a significant impact on MSA allocations.
  • CMS accepts amended submissions when the changes are supported by credible medical evidence and documentation.
  • Proactive clinical oversight helped reduce this allocation by $101,312 while maintaining compliance and settlement readiness.

Frequently Asked Questions About Amended Reviews

What is an amended review?

An amended review updates a previously CMS-approved MSA allocation when new medical information becomes available that affects future medical cost projections.

Why are amended reviews necessary?

Claims evolve over time. Updated medical records may reveal discontinued medications, reduced treatment frequency, or changes in provider recommendations that should be reflected in the allocation.

How does an amended review create savings?

 An amended review corrects outdated projections and aligns the allocation with current medical necessity. This can reduce unnecessary funding while maintaining compliance with CMS guidelines.

Can an MSA be changed after it has been approved by CMS?

Yes. If significant medical updates occur after submission, an amended review may be appropriate. Updated medical records, physician recommendations, and treatment changes can justify a revised Medicare Set Aside allocation.

 

 

CMS Section 111 Update: Key Changes to ORM Termination and TPOC Reporting

May 13, 2026

The Centers for Medicare and Medicaid Services (CMS) has released an update to the Section 111 NGHP User Guide (Version 8.4), introducing important clarifications related to:

  • Ongoing Responsibility for Medicals (ORM)
  • Total Payment Obligation to Claimant (TPOC) reporting
  • Wrongful death claims
  • Medicare Set-Aside (MSA) reporting in multi-defendant cases.

While many of these updates reinforce existing practices, several changes carry meaningful compliance implications for Responsible Reporting Entities (RREs).

Expanded Guidance on ORM Termination

CMS updated Chapter III, Section 6.3.2 of the Policy User Guide to clarify acceptable circumstances for terminating ORM.

The revised language states:

“Where the insurer’s responsibility for ORM has been terminated per the terms of the pertinent insurance contract, such as maximum coverage benefits, or any other reason that is not prohibited by the terms of the insurance contract or applicable state or federal law.”

CMS also added:

“Note: An insurer’s refusal to accept ORM, or to continue to accept ORM, is a valid ORM termination reason, provided that the refusal is permitted by applicable state or federal law and the terms of the insurance contract.”

What This Means

This update introduces helpful flexibility, but it does not create new substantive grounds for terminating ORM. Nonetheless, RREs may feel more comfortable with terminating ORM based on the following:

  • Claim denials
  • Independent Medical Examination (IME) results
  • Maximum Medical Improvement (MMI) determinations
  • Claimant non-compliance (e.g., refusal of treatment or IME)

In short, CMS has clarified when termination may be recognized, not expanded the legal basis for termination.

Clarification of TPOC Date in Workers’ Compensation Settlements

CMS also added a helpful example in Section 6.4 of the Policy Guide regarding the proper TPOC date to use when commission approval of a workers’ compensation case is required:

“Example: The parties to a workers’ compensation case execute an agreement regarding the claim on 01/20/2026. The state requires the workers’ compensation commission to approve the final settlement details and said approval occurs on 02/05/2026.”

According to CMS, the TPOC date is February 5, 2026, because it was the later of:

  • The date the agreement was fully executed
  • The date the court or commission approved the agreement.

What This Means

For many workers’ compensation settlements, this confirms what has already been standard industry practice: the commission approval date will be the TPOC date.

Updated Approach to Wrongful Death Claims

CMS also modified the language in Section 6.5.1.4 related to wrongful death claims.

Previously, CMS stated that wrongful death settlements were not reportable if they:

  • Did not claim or release medicals, and
  • Did not have the effect of releasing medicals

The revised language now emphasizes Medicare recovery rights and documentation.

“Note: In order for the wrongful death theory of liability to preclude Medicare from recovering from a settlement, judgment, award, or other payment, complete documentation must be provided that shows what was claimed and released or had the effect of being released. Additionally, a citation to the appropriate state statute or case law that precludes recovery from a wrongful death settlement should be included with any such dispute or appeal.

The prior language was:

Settlements, judgments, awards, or other payments entirely under the wrongful death theory of liability, which do not claim and release medicals, or have the effect of releasing medicals, are not required to be reported because Medicare would have no recovery claim against such a payment.

What This Means

It is unclear why CMS modified the language in this section, which shifts the focus from the release of medicals to recovery; however, the underlying requirements remain: a settlement is not reportable unless medicals are claimed and released as part of that settlement.  This includes a wrongful death settlement.

TPOC Reporting in Multi-Defendant Cases

CMS also clarified reporting requirements for multiple settlements involving the same claimant. The updated guidance confirms that where liability is proportionate or several, but not joint and several, each RRE should report only its own TPOC amount.

CMS added the language in bold:

Multiple settlements involving the same individual – If there will be multiple TPOCs submitted for the same individual, for the same incident, but reported by different RREs (proportionate or several liability but not joint and several), the records shall reflect each RRE’s unique TPOC amount and not the aggregate TPOC the beneficiary will be receiving. If more than one RRE has assumed responsibility for ongoing medicals, Medicare would be secondary to each such entity.

Example

If:

  • The total settlement is $100,000, and
  • One RRE’s share is $25,000

Then that RRE reports a TPOC amount of $25,000 — not the full settlement amount.

What This Means

This reinforces that reporting obligations where there is not joint and several liability are entity-specific, aligning each RRE’s reporting with its actual financial responsibility and avoiding over-reporting of settlement amounts.

The update helps avoid:

  • Over-reporting settlement amounts
  • Duplicate reporting
  • Confusion around proportional liability scenarios

Medicare Set-Aside (MSA) Reporting Clarifications

CMS also revised guidance regarding WCMSA reporting in cases involving:

  • Multiple dates of injury, or
  • Multiple defendants

CMS updated with new information in bold:

“As it relates to multiple dates of incident, an MSA, if applicable, shall be reported under the earliest date of incident, if only one TPOC is made. If multiple TPOCs are submitted, but only one MSA is reported, the MSA shall be reported on the first TPOC only. Where there are multiple defendants (RREs) reporting each RRE must report the total MSA Amount—not just its assigned or proportionate share. System logic exists such that only the first reported MSA amount will be applied for purposes of coordination of benefits.”

The updated language states that where multiple RREs are reporting, each RRE must report the full MSA amount — not merely its proportionate share.

CMS further notes that system logic applies only the first reported MSA amount for coordination of benefits purposes.

What This Means

This creates a notable distinction between:

  • Financial responsibility, and
  • Reporting obligations

Even where liability is divided, all RREs are required to report the entire MSA amount, making coordination among defendants critical to ensure consistency and avoid confusion.

Example (using the scenario above)

Assume:

  • Total settlement = $100,000
  • One RRE’s share = $25,000
  • WCMSA amount = $50,000

The RRE would report:

  • TPOC Amount: $25,000
  • WCMSA Amount: $50,000

Because all RREs must report the full MSA amount, coordination among defendants is critical to ensure consistency and avoid reporting discrepancies.

Final Thoughts

These updates do not fundamentally change Section 111 reporting—but they do tighten expectations around documentation, consistency, and defensibility.

RREs should review internal protocols, particularly around:

  • ORM termination decisions
  • Wrongful death claim handling
  • Coordination in multi-defendant settlements

Small missteps in these areas can create outsized compliance risk.

If you have any questions, please reach out to Tower’s Chief Compliance Officer, Dan Anders, at daniel.anders@towermsa.com .

 

From Backlog to Breakthrough, Reducing 43 Percent of Legacy Claims

May 5, 2026

Image of Tower MSA Partners Why Case Studies Matter series, Blog 8 Reducing Legacy Claims

A large payer came to Tower MSA Partners with a backlog of legacy claims that had stalled for months, and in some cases years. These claims included outdated medical records, unclear treatment histories, and MSAs that had never been reviewed for accuracy. Through structured medical review and focused cleanup, Tower helped the payer resolve 43% of these legacy claims. This case  reflects a broader trend in workers’ compensation, where successful legacy claim resolution depends on accurate clinical validation and updated MSA preparation.

Why Legacy Claims Stall

Legacy claims don’t linger because they are unsolvable, they stall because the underlying data is no longer accurate.

In this case:

  • Treatment histories no longer reflected current care
  • Medications included in MSAs had long been discontinued
  • Medical projections were based on outdated assumptions
  • Files had not been clinically reviewed in years

These issues led to inflated exposure, unclear settlement positions, and hesitation from all parties involved.

Turning Aging Files into Actionable Claims

Tower MSA Partners implemented a structured review process focused on clinical accuracy and defensibility.

Each claim was evaluated to:

  • Remove discontinued or unnecessary medications
  • Correct or eliminate outdated treatment projections
  • Align medical records with current care status
  • Rebuild MSAs based on actual medical necessity

Tower’s clinical team actively reconciles treatment patterns against real-world care. This ensures allocations reflect what is actually happening—not what was assumed years ago.

The result: MSAs that are accurate, defensible, and ready to support settlement.

How Collaboration Supports Legacy Claim Settlement

Updating the MSA alone is not enough—claims move when all stakeholders are aligned.

Tower worked closely with the claims team to clearly document and explain each change, giving adjusters confidence in the updated exposure. In parallel, structured settlement and professional administration partners were introduced to address claimant concerns about future medical care.

This combination helped:

  • Reduce claimant resistance
  • Eliminate uncertainty around future treatment funding
  • Create cleaner, more predictable submissions to CMS

Files that had been stagnant for years were now positioned for resolution.

Why Legacy Claim Resolution Makes a Difference

Without clinical validation, MSAs drift away from reality over time. They become inflated, difficult to defend, and harder to settle.

Tower’s approach restores alignment between medical documentation and actual care by:

  • Verifying current treatment status
  • Eliminating unsupported projections
  • Ensuring compliance with CMS expectations

This transforms legacy claims from uncertain liabilities into actionable settlement opportunities.

Results That Reflect Expertise

Through a focused legacy claim strategy:

  • 43% of legacy claims were resolved
  • Previously stalled files became settlement-ready
  • MSAs were updated to reflect current medical reality
  • Submissions were supported by clear, defensible documentation

What This Means for Payers

If you have claims that have not moved in years, there is a strong likelihood they are being driven by outdated medical assumptions—not true exposure.

Correcting those assumptions can unlock significant progress without increasing settlement spend.

Ready to Move Your Legacy Claims?

Tower MSA Partners helps payers reduce backlogs, improve MSA accuracy, and accelerate settlements through clinical intervention and disciplined review.

If you’re carrying aging claims that continue to stall, it may be time to reassess what’s driving them.

Contact our team or connect with Hany Abdelsayed, Executive Vice President, Strategic Services, at hany.abdelsayed@towermsa.com to discuss your legacy claim strategy.

Frequently Asked Questions

What is legacy claim resolution?

Legacy claim resolution is the process of reviewing long-standing or stalled claims to correct outdated medical projections and prepare accurate MSAs that support settlement.

Why do legacy claims stall?

They often include outdated treatments, discontinued medications, and unclear medical histories that make MSAs inaccurate or inflated.

How does Tower reduce legacy claim backlogs?

Tower updates records, verifies treatment plans, corrects pharmacy projections, and prepares accurate MSAs supported by current documentation.

Does CMS accept updated MSAs on old claims?

Yes. CMS accepts updated allocations when the documentation accurately reflects the claimant’s current medical needs.

How long does legacy claim resolution typically take?

The timeline depends on the condition of the claim files and the level of medical review required. Many legacy claims can move toward settlement within weeks once records are updated and MSAs are corrected to reflect current medical needs.

$210K Saved: Why Clinical Oversight Is the Hidden MSA Advantage

April 9, 2026

Image of Tower MSA Partners Why Case Studies Matter series, Blog 7 Clinical Oversight Savings

In Tower MSA Partners’ last post, $231K in Savings from Free Physicians Follow-Up, we demonstrated how ongoing medical review produced $231K in savings through free physician follow-up. This month, we highlight the broader impact of clinical oversight itself. A payer asked Tower MSA Partners to review a complex claim involving long-term pain management, active comorbidities, and multiple prescribing providers. Through clinical oversight, Tower identified inaccuracies and outdated treatments that reduced the projected allocation by $210,143 (approximately $210K). This case reinforces why clinical insight is a powerful advantage in Medicare Set-Aside (MSA) management.

Identifying the Problem

The claim had a long history of treatment, frequent medication changes, and overlapping specialties that created inconsistencies in documentation. The initial MSA prepared by another vendor included medications that were no longer prescribed, therapy frequencies that were inconsistent with current care, and several treatments that lacked documentation supporting ongoing medical necessity. Without clinical oversight, these issues would have resulted in inflated costs and potential CMS challenges. The payer needed an accurate allocation that reflected the claimant’s present health status and documented treatment plan.

The Clinical Oversight Solution

Tower MSA Partners conducted a comprehensive clinical review of all medical records, pharmacy histories, diagnostic reports, and provider notes. The clinical team identified medications that had been discontinued, adjusted prescription regimens based on updated records, and corrected treatment frequencies. The review also uncovered redundant therapies that no longer aligned with best practice guidelines. Each correction was supported with clinical rationale and evidence-based justification. After applying these corrections, the revised MSA decreased by $210K while meeting all CMS expectations for accuracy and documentation.

Collaboration and Communication

Tower’s team worked closely with the claims professional to explain each update and its clinical foundation. Clear communication ensured that all parties understood the reasoning behind each correction. Defense counsel and treating providers were involved as needed to validate treatment patterns and confirm medication changes. This collaborative approach helped create a strong, defensible MSA that moved through CMS review without additional development requests. Precise documentation and clinical clarity built confidence across the entire review chain.

Why Oversight Makes the Difference

Clinical oversight strengthens MSA accuracy by applying an evidence-based medical lens instead of a purely administrative review, ensuring allocations are clinically appropriate and defensible under CMS review. Over time, complex claims develop treatment patterns that do not always reflect current clinical standards or actual patient needs. By applying clinical judgment, Tower identifies outdated or unnecessary items that inflate lifetime costs and weaken compliance. This case shows how oversight protects payers from significant overfunding while ensuring the MSA remains a true reflection of medically necessary care.

Lessons Learned

·       Clinical oversight reveals inconsistencies that administrative reviews often miss.

·       Updated medical documentation ensures accurate and defensible MSA projections.

·       Collaboration with providers strengthens clarity around treatment plans.

·       Savings come from clinically guided corrections and accurate projections.

·       The $210K reduction resulted from correcting outdated services and aligning projections with best practice.

Results That Reflect Expertise

The payer saved $210K and gained a fully compliant, defensible MSA supported by updated medical documentation and evidence-based clinical review. Tower MSA Partners demonstrated how clinical insight delivers meaningful savings while strengthening the accuracy and defensibility of every allocation. Clinical oversight is an essential advantage in managing complex claims and achieving both cost containment and compliance excellence.

FAQs

What is clinical oversight in MSA review?
Clinical oversight is a medically guided evaluation of an MSA that ensures treatments and medications reflect current clinical standards and documented medical necessity.

How does clinical oversight reduce MSA costs?
It identifies outdated treatments, incorrect therapy projections, and discontinued medications that inflate lifetime medical costs.

When is clinical oversight most valuable?
It is essential for complex claims involving long-term treatment, multiple providers, or frequent medication changes.

Does CMS recognize clinically supported changes?
Yes. CMS accepts proposed MSA amounts when they are supported with accurate clinical documentation and clear reasoning.

 

 

Premier Webinar: MSP Compliance in 2026 – Regulatory Updates, Section 111 Audits & Settlement Risk

March 9, 2026

Tower MSA Partners webinar banner for “MSP Compliance in 2026, Section 111 Audits and Settlement Risk” on March 11, 2026 at 2 PM ET.

In 2025, the Medicare Secondary Payer landscape changed in meaningful ways. Section 111 WCMSA reporting became operational, and CMS discontinued formal review of $0 MSAs—fundamentally altering how payers approach settlement strategy and compliance risk.

Now in 2026, CMS is preparing to initiate its first round of Section 111 reporting audits.

What does all this mean for carriers, self-insureds, and defense counsel?

On Wednesday, March 11 at 2:00 p.m. ET, join Tower’s Chief Compliance Officer, Dan Anders, for a focused, practical discussion on how these regulatory developments are impacting workers’ compensation claims handling—and what organizations should be doing now.

You will learn:

  • The current status of Section 111 WCMSA reporting and how it is affecting settlement negotiations
  • What to expect from upcoming CMS Section 111 audits, including likely audit focus areas and compliance vulnerabilities
  • How to evaluate and document $0 MSAs in the absence of formal CMS review
  • Emerging MSA trends based on recent CMS guidance and Tower benchmarking data
  • Practical steps to mitigate civil money penalty exposure and strengthen internal controls

A Q&A session will follow the presentation. Questions may be submitted in advance during registration.

Please reserve your spot today.

Registration link: https://attendee.gotowebinar.com/register/3480677134558573406

 

$231K in Savings from Free Physician Follow-Up

March 4, 2026

Image of Tower MSA Partners Why Case Studies Matter series, Blog 6 $231K in Savings from Free Physicians Follow-Up.

In Tower MSA Partners’ previous post, Trimming the Fat, $175K in Savings Through MSA Optimization, we explained how MSA optimization removed $175,000 in unnecessary projected costs. In this case, a payer asked Tower to validate the treatment plan for a complex claim through physician follow-up. By engaging the treating provider, confirming current medical needs, and obtaining a physician attestation, Tower reduced the projected Medicare Set Aside (MSA) lifetime cost by $231,487 and secured CMS acceptance without development.

Identifying the Problem

The claimant’s original MSA had been created more than two years earlier. Since that time:

  • Multiple prescriptions were listed without up-to-date clinical context
  • Treatment frequency and diagnoses were not validated
  • The projected costs reflected outdated assumptions

Without direct clinical confirmation, the allocation risked inflating projected future costs and faced potential CMS scrutiny. The payer needed a defensible allocation grounded in current medical reality.

The Physician Follow-Up Solution

Tower’s clinical team initiated physician follow-up, adhering to jurisdictional rules for secure outreach. The process included:

  • Reviewing the full set of updated medical records
  • Confirming active medications, dosages, and indications
  • Discussing current therapy frequency with the treating physician
  • Validating the absence or tapering of unnecessary prescriptions

The physician confirmed that the only active prescription was Oxycodone/APAP 5/325 mg and that certain therapies were no longer needed. Armed with this clinical confirmation and a signed attestation, Tower updated the allocation.

The result was a $231,487 reduction in projected MSA costs — fully documented, fully supported, and defensible.

Collaboration and Communication

Tower MSA Partners didn’t just update numbers in a spreadsheet. Every correction was explained clearly to the claims professional and documented. The physician’s signed attestation — verifying current care and confirming that outdated items were no longer clinically necessary — was included in the CMS submission.

Because the revised MSA included accurate current clinical information and a valid attestation, CMS approved the allocation quickly and without development requests.

Why Physician Follow-Up Makes the Difference

Treatment plans evolve, medications change, and assumptions in an early allocation can become outdated. Without direct validation from the treating physician:

  • Medications may be mischaracterized
  • Frequencies may be overstated
  • Lifetime projections may overestimate future care

Physician follow-up ensures the MSA reflects actual current need, which:

  • Controls costs
  • Enhances compliance
  • Strengthens defensibility in CMS review

This case shows that physician engagement isn’t a luxury — it’s a strategic lever for both accuracy and savings.

Lessons Learned

  1. Physician engagement validates clinical need and clarifies current care.
  2. Signed attestations give CMS confidence in the accuracy of the allocation.
  3. Outdated medications and therapies can be confidently removed when confirmed to be clinically unnecessary.
  4. Defensible projections protect payers from excess costs and speed CMS review.

Results That Reflect Expertise

With targeted physician follow-up and attestation:

  • The payer realized $231,487 in reduced lifetime MSA costs
  • The updated allocation aligned with clinical reality
  • CMS approved the allocation without development requests

Tower MSA Partners delivered transparent documentation, accurate projections, and a cost-conscious, defensible settlement outcome.

FAQs

What is physician follow-up?

Physician follow-up is direct communication by Tower with the treating provider to confirm current medical treatment, active medications, and therapy needs. It ensures MSAs reflect accurate, individualized clinical information.

How does physician follow-up create savings?

By validating care with the treating physician, unnecessary treatments and medications can be removed or corrected in the lifetime projection, reducing projected future costs.

Is physician follow-up accepted by CMS?

Yes. When physician follow-up includes clear clinical documentation and, if required, a signed statement, CMS will accept updated MSAs and often approves them without development requests.

When should physician follow-up be used?

Physician follow-up can be used anytime there is open-ended medical care, outdated treatment recommendations or inconsistent or contradictory medication history.

Trimming the Fat, $175K in Savings Through MSA Optimization

February 3, 2026

Image of Tower MSA Partners Why Case Studies Matter series, Blog 5 Trimming the Fat with MSA Optimization

In Tower MSA Partners’ previous post, we showed how a MSA second opinion review helped a payer avoid ninety-eight thousand dollars in unnecessary allocation. This month, we look at a case study on how targeted MSA optimization can uncover even larger savings. Tower MSA Partners reviewed a complex claim with significant pharmacy exposure and identified an opportunity to reduce projected costs by $175,000. This case shows how structured review protocols and clinical oversight create precise and defensible MSAs.

Identifying the Problem

The claimant had a long-term injury that included frequent therapy, diagnostics, and multiple ongoing prescriptions. The initial MSA prepared by another vendor included duplicate entries, outdated treatments, and medications that had been replaced with safer and more cost-effective alternatives. Therapy frequency was also projected far beyond what the medical records supported. These inaccuracies created an inflated allocation that did not reflect current treatment patterns.

The MSA Optimization Solution

Tower MSA Partners completed a full optimization review and reconciled every projection with the latest medical records. Our clinical team verified treatment frequency, evaluated pharmacy histories, and confirmed whether each medication remained clinically appropriate. Outdated therapy, legacy prescriptions, and inaccurate frequency projections were removed or corrected. Each modification included detailed clinical reasoning and clear documentation. After optimization, the MSA decreased by $175,000 and remained fully aligned with CMS expectations. The updated allocation represented the claimant’s true medical needs without unnecessary inflation.

Collaboration and Communication

As with all Tower reviews, collaboration played a significant role. The clinical team walked the claims professional through each correction and clarified why the original allocation overstated ongoing care. Defense counsel and treating providers were updated as needed to confirm accuracy and alignment with the medical record. The optimized MSA was submitted to CMS with strong supporting documentation and was approved without development requests.

Why Oversight Makes the Difference

MSA optimization is not simply cost-cutting. It is a structured validation process that ensures every projected service is clinically necessary and supported by current documentation. Removing outdated items protects payers and claimants from unnecessary costs and strengthens the defensibility of every file. This case demonstrates how careful review drives savings.

Lessons Learned

  1. MSA optimization identifies inaccurate or outdated projections that inflate lifetime medical costs.
  2. Clinical oversight ensures medications and treatments reflect current best practice.
  3. Documentation clarity leads to predictable CMS approval.
  4. Savings come from precision. The $175,000 reduction resulted from accurate alignment with the medical record.

Results That Reflect Expertise

The optimized MSA saved the payer settlement monies and produced a compliant, defensible allocation supported by current documentation. Tower MSA Partners continues to demonstrate how clinical accuracy, alignment with CMS, and detail-oriented review generate meaningful and measurable results. Optimization is an essential tool in responsible claims management.

FAQs

What is MSA optimization

MSA optimization is a detailed clinical review that removes outdated treatments, corrects inaccurate projections, and ensures the allocation reflects current medical necessity.

How does optimization reduce allocation amounts

Optimization aligns treatment and pharmacy projections with the actual medical record, which eliminates unnecessary costs and outdated services.

When should an MSA be optimized

It is recommended for claims with long-term treatment, complex pharmacy needs, or significant changes in care since the initial projection.

Does CMS accept optimized MSAs

Yes. CMS accepts optimized MSAs when the updated allocation includes clear clinical documentation and accurate reasoning for the projected future medical.